Oppenheimer analyst Leland Gershall reiterated an Outperform rating on Capricor Therapeutics (NASDAQ: CAPR).The analyst commented: "Briefing documents for this Wednesday's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE